| Literature DB >> 11950570 |
Eva Stoger1, Markus Sack, Rainer Fischer, Paul Christou.
Abstract
Various strategies have been developed to exploit plants as bioreactors for the production of pharmaceutical antibodies, to engineer antibody-mediated pathogen resistance or to alter the plant phenotype by immunomodulation. Recent research developments focus on the fine-tuning of expression systems and the detailed characterisation of recombinant products, including the implications of plant-specific glycosylation. Meanwhile, the first of these plant-derived antibody products has successfully completed early phase clinical trials.Mesh:
Substances:
Year: 2002 PMID: 11950570 DOI: 10.1016/s0958-1669(02)00303-8
Source DB: PubMed Journal: Curr Opin Biotechnol ISSN: 0958-1669 Impact factor: 9.740